NeOnc Technologies Holdings, Inc
NEONC TECHNOLOGIES HOLDINGS, INC. is a U.S.-based clinical-stage biopharmaceutical company developing therapies for malignant brain cancers. Its lead program, NEO100, is being tested as an intranasal treatment in Phase 2a, while NEO212 and other candidates remain in preclinical or early clinical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2024–2025
Liiketoiminta
Osuus liikevaihdostaIntranasal therapy being evaluated in Phase 1 and Phase 2a studies for malignant glioma and related brain tumors.
Second oncology candidate that has completed preclinical testing and entered early clinical development.
Additional drug candidates under discovery and preclinical development for future oncology indications.
Occasional fees received from patients under a right-to-try humanitarian program.
Asiakkaat
The company’s direct end users are patients with malignant brain cancers, especially recurrent glioma and other primary or secondary malignant brain tumors. Commercially, any future sales would depend on oncologists, hospitals, and third-party payors that decide whether the therapy is clinically useful, covered, and reimbursable. Until approval and commercialization, the company’s “customers” are largely clinical investigators, trial sites, and potential licensing or commercialization partners.
Patients with recurrent or primary malignant brain tumors who may receive NEO100 or NEO212 in trials or future approved use.
Hospitals, physicians, and research centers that enroll patients and generate the safety/efficacy data needed for approval.
Insurers and reimbursement bodies that would determine whether approved products are covered and economically viable.
Pharma or biotech partners that could license, market, or distribute products in foreign markets.
Strategia
The company’s strategy is to advance NEO100 and NEO212 through clinical development, secure regulatory approval, and then decide whether to commercialize directly or through partners. Because it has no approved products, the near-term focus is funding, trial execution, manufacturing readiness, and intellectual property protection rather than sales expansion.
The lead asset must show safety and efficacy before any commercial value can be realized.
A broader pipeline increases the chance of eventual approval and reduces single-asset dependence.
The company needs external capital and may need collaborators to fund development and commercialization.
Maantiede
The company is headquartered in the United States and its development work is centered on U.S. regulatory pathways, including FDA review of NEO212. Management also contemplates partnering or licensing in foreign markets if products are approved, but no country-level revenue concentration is disclosed because the company has not generated meaningful product sales. Geography currently matters more as a regulatory and commercialization issue than as a revenue driver.
Riskit
NEONC is a pre-revenue biotech with substantial going-concern and financing risk, so its ability to continue operations depends on raising capital and advancing clinical programs. Its commercial opportunity also depends on regulatory approval, manufacturing execution, reimbursement, and competition from better-funded oncology developers. Because it relies on third parties for research, manufacturing, and potential commercialization, operational setbacks can directly delay or eliminate value creation.
- Going concern and funding shortfallVaikutus: KriittinenTodennäköisyys: Korkea
The company has substantial losses, limited revenue, and needs external capital to fund trials and operations.
Kohdistuu: Could delay or terminate development programs and commercialization plans.
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
NEO100 and NEO212 must prove safety and efficacy and obtain FDA approval before generating meaningful revenue.
Kohdistuu: A negative trial or regulatory decision could eliminate the lead asset's value.
- Manufacturing and third-party relianceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on external parties for ingredients, testing, and manufacturing support.
Kohdistuu - Commercialization and reimbursement riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Even if approved, uptake depends on payor coverage, physician adoption, and market access.
Kohdistuu: Could limit sales and delay profitability.
- Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Larger biopharma and biotech firms may develop safer or more effective therapies faster.
Kohdistuu: Could reduce or eliminate commercial opportunity in brain cancer.
Kirjanpito
Harkinnanvaraiset erätRSU fair values, vesting schedules, and forfeiture estimates directly affect operating expenses.
Vaikutus: Can materially change reported loss and quarterly comparability
Occasional right-to-try fees are not part of product sales and may be sporadic.
Vaikutus: Revenue is not representative of commercial traction
Liquidity assumptions and funding plans are central to financial statement presentation.
Vaikutus: Signals uncertainty around continuation of operations
Advances and conversions from insiders affect equity, debt, and dilution analysis.
Vaikutus: Can influence leverage, ownership, and cash runway
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Oragenics Inc
OGEN · Pharmaceutical Preparations
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Neuphoria Therapeutics Inc.
NEUP · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Päivitetty: 24.9.2026